Antibiotic therapy for pediatric community-acquired pneumonia: Do we know when, what and for how long to treat?

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages

  Esposito, Susanna ^a   Cohen, Robert ^b   Domingo, Javier Diez ^c   Pecurariu, Oana Falup ^d   Greenberg, David ^e   Heininger, Ulrich ^f   Knuf, Markus ^g,h   Lutsar, Irja ⁱ   Principi, Nicola ^a   Rodrigues, Fernanda ^j   Sharland, Mike ^k   Spoulou, Vana ^l   Syrogiannopoulos, George A ^m   Usonis, Vytautas ⁿ   Vergison, Anne ^o,p   Schaad, Urs B ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^d TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g UNIVERSITY OF BASEL   (Switzerland)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ DR HORST SCHMIDT KLINIKEN   (Germany)

^j UNIVERSITY OF TARTU   (Estonia)

^k CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^l ST GEORGE S HOSPITAL   (United Kingdom)

^m AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

ⁿ UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^o VILNIUS UNIVERSITY   (Lithuania)

^p HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

more..

Author keywords

Antibiotics; Antimicrobial treatment; Community acquired pneumonia; Pneumonia; Respiratory infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CEFALEXIN; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; CLOXACILLIN; ERYTHROMYCIN; GENTAMICIN; MACROLIDE; PENICILLIN G; SIALIDASE INHIBITOR; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CHILDHOOD DISEASE; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL PNEUMONIA; CHLAMYDIASIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYANOSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; ESCHERICHIA COLI; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; HYPOXEMIA; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; OXYGEN SATURATION; PERTUSSIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCAL PNEUMONIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT DURATION; VACCINATION;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PNEUMONIA, BACTERIAL; TIME FACTORS;

EID: 84861527499     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318255dc5b     Document Type: Review

References (106)

1. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346:429-437.
2. Principi N, Esposito S. Paediatric community-acquired pneumonia: current concept in pharmacological control. Expert Opin Pharmacother. 2003;4:761-777.
3. Principi N, Esposito S. Management of severe community-acquired pneumonia of children in developing and developed countries. Thorax. 2011;66:815-822.
4. Atkinson M, Yanney M, Stephenson T, et al. Effective treatment strategies for paediatric community-acquired pneumonia. Expert Opin Pharmacother. 2007;8:1091-1101.
5. Harris M, Clark J, Coote N, et al. British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(suppl 2):ii1-ii23.
6. Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:617-630.
7. Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2008;CD005976.
8. Shoham Y, Dagan R, Givon-Lavi N, et al. Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life. Pediatrics. 2005;115:1213-1219.
9. Esposito S, Principi N. Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Drug Resist Updat. 2002;5:73-87.
10. Thomson RB Jr. Laboratory diagnosis of respiratory infections. Curr Opin Infect Dis. 1999;12:115-119.
11. Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ. 1997;156:S703-S711.
12. McCracken GH. Etiology and treatment of pneumonia. Pediatr Infect Dis J. 2000;19:273-277.
13. Menéndez R, Córdoba J, de La Cuadra P, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med. 1999;159:1868-1873.
14. Juvén T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293-298.
15. Cheuk DK, Tang IW, Chan KH, et al. Rhinovirus infection in hospitalized children in Hong Kong: a prospective study. Pediatr Infect Dis J. 2007;26:995-1000.
16. Tsolia MN, Psarras S, Bossios A, et al. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis. 2004;39:681-686.
17. Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet. 2011;377:1264-1275.
18. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(suppl 4):S284-S289.
19. Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J. 1998;17:986-991.
20. Resti M, Moriondo M, Cortimiglia M, et al. Italian Group for the Study of Invasive Pneumococcal Disease. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis. 2010;51:1042-1049.
21. Marchese A, Esposito S, Coppo E, et al. Detection of Streptococcus pneumoniae and identification of pneumococcal serotypes by real-time polymerase chain reaction using blood samples from Italian children = 5 years of age with community-acquired pneumonia. Microb Drug Resist. 2011;17:419-424.
22. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimi crobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2011.
23. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197-e209.
24. Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine. 2008;26(suppl 2):B19-B23.
25. Vergison A, Tuerlinckx D, Verhaegen J, et al. Belgian Invasive Pneumococcal Disease Study Group. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics. 2006;118:e801-e809.
26. Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30:227-233.
27. Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J. 2009;28:43-48.
28. Kalies H, Siedler A, Gröndahl B, et al. Invasive Haemophilus influenzae infections in Germany: impact of non-type b serotypes in the post-vaccine era. BMC Infect Dis. 2009;9:45.
29. McCracken GH. Diagnosis and management of pneumonia in children. Pediatr Infect Dis J. 2000;19:924-928.
30. Beekmann SE, Heilmann KP, Richter SS, et al. GRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents. 2005;25:148-156.
31. Pérez-Trallero E, Martín-Herrero JE, Mazón A, et al. Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother. 2010;54:2953-2959.
32. Couloigner V, Levy C, Francois M, et al. Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels. Pediatr Infect Dis J. 2012;31:154-158.
33. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010;10:227-239.
34. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616-687.
35. Niniou I, Vourli S, Lebessi E, et al. Clinical and molecular epidemiology of community-acquired, methicillin-resistant Staphylococcus aureus infections in children in central Greece. Eur J Clin Microbiol Infect Dis. 2008;27:831-837.
36. Katopodis GD, Grivea IN, Tsantsaridou AJ, et al. Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis. 2010;10:351.
37. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995;14:471-477.
38. Principi N, Esposito S, Blasi F, et al. Mowgli Study Group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001;32:1281-1289.
39. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis. 2001;1:334-344.
40. Baer G, Engelcke G, Abele-Horn M, et al. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents. Eur J Clin Microbiol Infect Dis. 2003;22:742-745.
41. Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009;64:52-58.
42. Dumke R, von Baum H, Lück PC, et al. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010;16:613-616.
43. Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011;66:734-737.
44. Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerging Infect Dis. 2011;17:1079-1082.
45. Morozumi M, Iwata S, Hasegawa K, et al. Acute Respiratory Diseases Study Group. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52:348-350.
46. Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis. 2010;67:355-358.
47. Cao B, Zhao CJ, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51:189-194.
48. Cilla G, Oñate E, Perez-Yarza EG, et al. Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. J Med Virol. 2008;80:1843-1849.
49. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-707.
50. Wolf DG, Greenberg D, Shemer-Avni Y, et al. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr. 2010;156:115-120.
51. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis. 2002;186:341-350.
52. Hament JM, Aerts PC, Fleer A, et al. Enhanced adherence of Streptococcus pneumoniae to human epithelial cells infected with respiratory syncytial virus. Pediatr Res. 2004;55:972-978.
53. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J. 2011;30:11-18.
54. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811-813.
55. Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis. 2006;193:1236-1243.
56. Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J. 2011;30:545-550.
57. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805-811.
58. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52:24-36.
59. Lutsar I, Friedland I. van den Anker JN, eds. Clinical trials of anti-infective agents in paediatrics. In: Rose K, van den Anker JN, eds. Guide to Paediatric Drug Development and Clinical Research. Basel: Karger; 2010:170-177.
60. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration. 2005;72:561-571.
61. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:35-40.
62. Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med. 2004;117(suppl 3A):16S-22S.
63. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J. 1997;16:438-443.
64. Giachetto G, Pirez MC, Nanni L, et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospitalized children with community-acquired pneumonia. Pediatr Infect Dis J. 2004;23:625-629.
65. Fonseca W, Hoppu K, Rey LC, et al. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother. 2003;47:997-1001.
66. Dulaney Lopez AM, Rodriguez JC, Lopez-Samblas AM, et al. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study. Int J Clin Pharmacol Ther. 1999;37:269-274.
67. Fukumoto K, Aida S, Oishi T, et al. Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients. Biol Pharm Bull. 2009;32:1139-1141.
68. del Rio Mde L, Chrane DF, Shelton S, et al. Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis. Antimicrob Agents Chemother. 1982;22:990-994.
69. Johnson JR, Colombo DF, Gardner D, et al. Optimal dosing of penicillin G in the third trimester of pregnancy for prophylaxis against group B Streptococcus. Am J Obstet Gynecol. 2001;185:850-853.
70. Meyers BR, Wilkinson P, Mendelson MH, et al. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob Agents Chemother. 1991;35:2098-2101.
71. Del Tacca M, Pasqualetti G, Di Paolo A, et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol. 2009;68:34-42.
72. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
73. Nazarian DJ, Eddy OL, Lukens TW, et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 2009;54:704-731.
74. Clark JE, Hammal D, Spencer D, et al. Children with pneumonia: how do they present and how are they managed? Arch Dis Child. 2007;92:394-398.
75. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110(1 pt 1):1-6.
76. Thompson M, Coad N, Harnden A, et al. How well do vital signs identify children with serious infections in paediatric emergency care? Arch Dis Child. 2009;94:888-893.
77. Langley JM, Bradley JS. Defining pneumonia in critically ill infants and children. Pediatr Crit Care Med. 2005;6(3 suppl):S9-S13.
78. Mamtani M, Patel A, Hibberd PL, et al. A clinical tool to predict failed response to therapy in children with severe pneumonia. Pediatr Pulmonol. 2009;44:379-386.
79. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45:315-321.
80. Castaldo ET, Yang EY. Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: an emerging fatal problem. Am Surg. 2007;73:684-687.
81. Techasaensiri B, Techasaensiri C, Mejías A, et al. Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J. 2010;29:519-523.
82. Jansen AG, Sanders EA, Hoes AW, et al. Influenza-and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007;30:1158-1166.
83. Demers AM, Morency P, Mberyo-Yaah F, et al. Risk factors for mortality among children hospitalized because of acute respiratory infections in Bangui, Central African Republic. Pediatr Infect Dis J. 2000;19:424-432.
84. Korppi M, Heiskanen-Kosma T, Leinonen M. White blood cells, C-reactive protein and erythrocyte sedimentation rate in pneumococcal pneumonia in children. Eur Respir J. 1997;10:1125-1129.
85. Korppi M, Remes S. Serum procalcitonin in pneumococcal pneumonia in children. Eur Respir J. 2001;17:623-627.
86. Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis. 2002;35:1345-1352.
87. Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002;57:438-441.
88. Korppi M, Kiekara O, Heiskanen-Kosma T, et al. Comparison of radiological findings and microbial aetiology of childhood pneumonia. Acta Paediatr. 1993;82:360-363.
89. Ben Shimol S, Dagan R, Givon-Lavi N, et al. Evaluation of the World Health Organization criteria for chest radiographs for pneumonia diagnosis in children. Eur J Pediatr. 2012;171:369-374.
90. Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ. 2005;83:353-359.
91. Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126:e865-e873.
92. Greenberg D, Chiou CC, Famigilleti R, et al. Problem pathogens: paediatric legionellosis-implications for improved diagnosis. Lancet Infect Dis. 2006;6:529-535.
93. Jain S. Perinatally acquired Chlamydia trachomatis associated morbidity in young infants. J Matern Fetal Med. 1999;8:130-133.
94. Rours GI, Hammerschlag MR, Van Doornum GJ, et al. Chlamydia trachomatis respiratory infection in Dutch infants. Arch Dis Child. 2009;94:705-707.
95. von König CH, Halperin S, Riffelmann M, et al. Pertussis of adults and infants. Lancet Infect Dis. 2002;2:744-750.
96. Greenberg D, Bamberger E, Ben-Shimol S, et al. Pertussis is under diagnosed in infants hospitalized with lower respiratory tract infection in the pediatric intensive care unit. Med Sci Monit. 2007;13:CR475-CR480.
97. Bamberger E, Starets-Haham O, Greenberg D, et al. Adult pertussis is hazardous for the newborn. Infect Control Hosp Epidemiol. 2006;27:623-625.
98. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. 1999;20:25-41.
99. Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007;26:868-878.
100. Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995;14:1-9.
101. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am. 2005;19:617-628.
102. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J. 2007;26:865-867.
103. Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax. 2007;62:1102-1106.
104. Peltola H, Vuori-Holopainen E, Kallio MJ; SE-TU Study Group. Successful shortening from seven to four days of parenteral beta-lactam treatment for common childhood infections: a prospective and randomized study. Int J Infect Dis. 2001;5:3-8.
105. Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.
106. Esposito S, Tagliabue C, Picciolli I, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105:1939-1945.